Lixisenatide for type 2 diabetes mellitus
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Lixisenatide for type 2 diabetes mellitus. / Christensen, Mikkel; Knop, Filip K; Vilsbøll, Tina; Holst, Jens Juul.
In: Expert Opinion on Investigational Drugs, Vol. 20, No. 4, 2011, p. 549-57.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Lixisenatide for type 2 diabetes mellitus
AU - Christensen, Mikkel
AU - Knop, Filip K
AU - Vilsbøll, Tina
AU - Holst, Jens Juul
PY - 2011
Y1 - 2011
N2 - Introduction: Type 2 diabetes mellitus (T2DM) is an increasing health problem worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiological traits of T2DM. Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM. Areas covered: Pharmacological, preclinical and clinical evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed. Available data and pending clinical development are summarized, critically appraised and compared to competitor drugs. The most relevant papers and meeting abstracts published up to November 2010 are used as sources for this review. Expert opinion: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin. However, limited data with the intended once-daily 20 µg subcutaneous dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments. It remains to be established whether the slightly differing chemical properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin. Read More: http://informahealthcare.com/doi/abs/10.1517/13543784.2011.562191
AB - Introduction: Type 2 diabetes mellitus (T2DM) is an increasing health problem worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiological traits of T2DM. Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM. Areas covered: Pharmacological, preclinical and clinical evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed. Available data and pending clinical development are summarized, critically appraised and compared to competitor drugs. The most relevant papers and meeting abstracts published up to November 2010 are used as sources for this review. Expert opinion: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin. However, limited data with the intended once-daily 20 µg subcutaneous dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments. It remains to be established whether the slightly differing chemical properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin. Read More: http://informahealthcare.com/doi/abs/10.1517/13543784.2011.562191
KW - Animals
KW - Clinical Trials as Topic
KW - Diabetes Mellitus, Type 2
KW - Drug Evaluation, Preclinical
KW - Drug Therapy, Combination
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Hypoglycemic Agents
KW - Metformin
KW - Peptides
U2 - 10.1517/13543784.2011.562191
DO - 10.1517/13543784.2011.562191
M3 - Journal article
C2 - 21391833
VL - 20
SP - 549
EP - 557
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
SN - 1354-3784
IS - 4
ER -
ID: 34145317